NEW YORK (GenomeWeb) – Epigenomics today announced that the US Food and Drug Administration has requested further data before making a decision on whether to approve the firm's blood-based colorectal cancer screening test.

Epigenomics has received a response letter from the FDA providing guidance and recommendations for improving the pre-market approval application for the German molecular diagnostics firm's Epi proColon screening test. The FDA requested additional data showing that the test will increase compliance to colorectal cancer screening in the intended use population.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.